Allogene Therapeutics

Traded on the St. Petersburg Stock Exchange
Allogene Therapeutics, with headquarters in South San Francisco, is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) therapies for cancer.
Allogene Therapeutics stock price chart
-16%
P/E
Net profit
P/B
Book value
P/FCF
FCF
Yield
Growth potential

Allogene Therapeutics balance sheet

Report period2018 2019 2020 2021 2022 Q3 23
End date of the reporting period
Capitalization, $
Capitalization, $
Enterprise Value
Book Value
Shareholders Book Value
Current liabilities
Noncurrent liabilities
Total liabilities
Debt
Cash and cash equivalents
Net debt
Assets
Total ordinary shares
Ordinary share price

Allogene Therapeutics cash flows

Report period2018 2019 2020 2021 2022 Q3 23 TTM
End date of the reporting period
Sales
Operation Income
Earnings
Shareholders earnings
EBITDA
Operation Cashflow
Capital expenditure
Free Cash Flow
EPS

Allogene Therapeutics multipliers

Report period2018 2019 2020 2021 2022 Q3 23 TTM
P/E
E/P
P/B
P/S
P/FCF
L/A
Debt-To-Equity
Net Debt/EBITDA
EV/EBITDA

Allogene Therapeutics profitability

Report period2018 2019 2020 2021 2022 Q3 23 TTM
ROA
ROE
ROS
EBITDA Margin
Operating margin
Allogene Therapeutics assets
Allogene Therapeutics cash flows

Allogene Therapeutics shares

TickerNameTypeNominal valueISINPrice
ALLO:USAllogene Therapeutics, Inc.Common share-US0197701065$4.26
Allogene Therapeutics news
01.03.2023
Allogene Therapeutics' GAAP loss for 2022 was $332.63 million, up 29.4% from $257 million the previous year. Revenues were down multiple times, at $0.243 million, compared to $38.489 million a year earlier.
03.11.2022
Allogene Therapeutics reported a GAAP loss of $237.785 million for 9 months of 2022, up 30.6% from $182.137 million in the prior year. Revenue decreased 99.5% to $0.196 million from $38.438 million a year earlier.
10.08.2022
Allogene Therapeutics' GAAP loss for 6 months of 2022 was $154.64 million, up 48.8% from $103.95 million in the previous year. Revenues declined multiple times, totaling $0.147 million versus $38.389 million a year earlier.
05.05.2022
Allogene Therapeutics' GAAP net income for 3 months of 2022 was $79.85 million, up 2.4 times from $33.015 million in the previous year. Revenues decreased many-fold, amounting to $0.061 million compared to $38.345 million a year earlier.
General information
Company nameAllogene Therapeutics
Tags#biotechnology
SectorHealth Care / Pharmaceuticals, Biotechnology & Life Sciences / Biotechnology / Biotechnology
Business address210 EAST GRAND AVENUE SOUTH SAN FRANCISCO CA 94080 (650) 457-2700
Mailing address210 EAST GRAND AVENUE SOUTH SAN FRANCISCO CA 94080
Websitewww.allogene.com
Information disclosurewww.sec.gov